DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the PE ratio of Concord Drugs Ltd?

Concord Drugs Ltd has a price-to-earnings (PE) ratio of 89.8 in the Healthcare sector.

What is the market capitalisation of Concord Drugs Ltd?

Concord Drugs Ltd has a market capitalisation of approximately ₹100 crore.

Concord Drugs Ltd

CONCORDDRUGSLTD·NSE·Healthcare

₹0.00▲ +0.00 (+0.00%)

⚠️Trading suspended. Not a live price.

Healthcare · Pharmaceuticals

A steady, established business

52W₹49

₹93-113%

Open

—

High

—

Low

—

Prev Close

—

Volume

—

VWAP

—

Snapshot

Key fundamentals

Market Cap

₹100 Cr

P/E Ratio

89.80Expensive

P/B Ratio

1.95

EPS

₹0.30

Book Value

₹36.82

ROE

2.52%Weak

ROCE

4.73%Weak

Dividend Yield

0.00%

Debt / Equity

0.24Low

Face Value

₹10.00

52W High

₹92.52

52W Low

₹49.00

Sector

Healthcare

Industry

Pharmaceuticals

Expensive

None moatHigh uncertainty

Fair value estimate

₹26

No recent traded price

BearFair valueBull

₹3₹26₹32

/100

Business quality — Watch the fundamentals

Growth 50Profitability 0Efficiency 0Valuation 44

Plain English

Our view

A steady, established business
Low debt relative to equity
Weak returns on equity (3%)

Strengths

Low debt relative to equity
Promoters hold a controlling stake

Risks

Weak returns on equity (3%)
Expensive — trades at 90× earnings

How we got there

Fair value methods

Residual income

1% ROE fading to 12% over ~3 yrs, on ₹37 book

₹32

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹3

Analyst target

No analyst coverage

—

Blended fair value₹26

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Promoters hold a controlling stake

Bear case

Weak returns on equity (3%)
Expensive — trades at 90× earnings

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

89.8Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

2.5%Weak

Above 15% is considered healthy for Indian equities

ROCE

4.7%Weak

Above 18% means capital is working hard

Debt/Eq

0.24Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹100 Cr

P/B

1.95

EPS

₹0.30

Div Yield

—

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Expensive

P/E 89.8×

Growth

Strong

+15% rev CAGR

Profitability

Modest

2.5% ROE

Financial health

Rock solid

D/E 0.24

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+15.3%

+8.9%

10Y

+4.5%

Profit

+5.7%

-20.4%

10Y

-5.0%

EPS

-78.2%

-69.4%

10Y

-42.2%

Profile

Pros

Company has reduced debt.
Company is expected to give good quarter

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
Company has low interest coverage ratio.
The company has delivered a poor sales growth of 8.12% over past five years.
Company has a low return on equity of 1.63% over last 3 years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

54%

Promoter

Promoters

54.4%0.00

Public

44.7%-0.30

FII / FPI

0.0%0.00

DII

0.0%0.00

Others

0.9%

Total shareholders

4,464-133 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter54.39%

Public44.66%

Others0.95%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1995, Concord Drugs Ltd manufactures licensed drugs based on approved formulations